Patent ID: 11878000
Assignee: CEDARS-SINAI MEDICAL CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of sensitizing cancer or precancerous cells present in a subject to the treatment with a tyrosine kinase inhibitor (TKI), the method comprising administering to a subject in need of TKI treatment:
a TKI in an amount and concentration sufficient to cause a cancer cell growth inhibiting and/or apoptosis-inducing TKI effect when administered to the subject together with, or in presence of, one or more sensitizer compound, wherein the TKI is not conjugated to the sensitizer compound; and
a sensitizer compound, in an amount and concentration sufficient to provide cancer cell sensitivity to the tyrosine kinase inhibitor, thus allowing for an enhanced effect of the TKI compared to a TKI administered in absence of the sensitizer compound;, wherein the cancer or precancerous cells are of a cancer that develops TKI resistance, the cancer that develops TKI resistance comprising: a cancer that is associated with tyrosine kinase abnormalities, a cancer which overexpresses a tyrosine kinase, and a cancer associated with mutations that lead to EGFR overexpression;, wherein the sensitizer compound is a DZ1-drug amide or ester conjugate comprising a drug residue,, and wherein the drug forming the drug residue is selected from the group consisting of a statin drug, a platin-based anti-neoplastic drug, and artemisinin, and wherein the DZ1 residue is selected from an amide and an ester-linked residue shown in formulae FI and FII below:, , wherein ˜ represents a point of attachment to the drug residue.